| 前收盘价格 | 10.70 |
| 收盘价格 | 10.59 |
| 成交量 | 579,045 |
| 平均成交量 (3个月) | 1,234,793 |
| 市值 | 1,746,719,872 |
| 预期市盈率 (P/E Forward) | 20.49 |
| 价格/销量 (P/S) | 4.60 |
| 股市价格/股市净资产 (P/B) | 1.64 |
| 52周波幅 | |
| 利润日期 | 26 Feb 2025 - 3 Mar 2025 |
| 营业毛利率 | -8.34% |
| 营业利益率 (TTM) | 6.74% |
| 稀释每股收益 (EPS TTM) | -0.200 |
| 季度收入增长率 (YOY) | 10.80% |
| 总债务/股东权益 (D/E MRQ) | 29.53% |
| 流动比率 (MRQ) | 2.86 |
| 营业现金流 (OCF TTM) | 54.42 M |
| 杠杆自由现金流 (LFCF TTM) | 70.56 M |
| 资产报酬率 (ROA TTM) | 0.59% |
| 股东权益报酬率 (ROE TTM) | -2.95% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Health Information Services (US) | 混合的 | 看跌 |
| Health Information Services (全球的) | 混合的 | 看跌 | |
| 股票 | Certara, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.3
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.25 |
|
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region. |
|
| 部门 | Healthcare |
| 行业 | Health Information Services |
| 投资方式 | Small Core |
| 内部持股比例 | 2.59% |
| 机构持股比例 | 95.94% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 16.00 (UBS, 47.47%) | 购买 |
| 中 | 13.00 (19.82%) | |
| 低 | 12.00 (Barclays, 10.60%) | 保留 |
| 平均值 | 13.67 (25.99%) | |
| 总计 | 1 购买, 2 保留 | |
| 平均价格@调整类型 | 11.02 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barclays | 07 Nov 2024 | 12.00 (10.60%) | 保留 | 10.99 |
| 15 Oct 2024 | 14.00 (29.03%) | 保留 | 11.21 | |
| Baird | 05 Nov 2024 | 13.00 (19.82%) | 保留 | 10.31 |
| UBS | 27 Sep 2024 | 16.00 (47.47%) | 购买 | 11.75 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 02 Dec 2024 | 公告 | Certara Showcases 2024 Research Wins With Over 100 Papers Published |
| 06 Nov 2024 | 公告 | Certara Reports Third Quarter 2024 Financial Results |
| 28 Oct 2024 | 公告 | Certara to Participate in the Stephens Annual Investment Conference |
| 16 Oct 2024 | 公告 | Certara Appoints John Reynders as New Independent Board Member |
| 09 Oct 2024 | 公告 | Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 |
| 02 Oct 2024 | 公告 | Certara Completes Acquisition of Chemaxon |
| 02 Oct 2024 | 公告 | Certara Completes Acquisition of Chemaxon |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合